Leukemia: all 5,475 studies
Page 49 of 55. Open to participants first (629), then studies with results posted, then the rest; newest registration first within each.
- WT1 for the Detection of Minimal Residual DiseaseCompletedNCT00179829Phase 2/3
- Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])CompletedNCT00179764Not applicable
- Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative DiseaseTerminatedNCT00176475Phase 1
- Differentiation Induction in Acute Myelogenous LeukemiaCompletedNCT00175812Phase 1/2
- Bone Marrow Angiogenesis in Acute Myeloid Leukemia - Evaluated by Dynamic Contrast Enhanced Magnetic Resonance (MR) ImageStatus unknownNCT00172562
- Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase EnzymesCompletedNCT00171912Phase 2
- Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)CompletedNCT00171899Phase 4
- Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) LeukemiaCompletedNCT00167167Not applicable
- Treatment of Acute Lymphoblastic Leukemia in ChildrenCompletedNCT00165178Phase 3
- Treatment of Childhood Acute Lymphoblastic LeukemiaTerminatedNCT00165087Phase 3
- Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid LeukemiaWithdrawnNCT00162513Phase 1/2
- Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in IsraelCompletedNCT00159003
- Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium TrisalicylateTerminatedNCT00156299Phase 1
- Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing Through"Marrow-Blood Barrier"Status unknownNCT00155844
- Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic LeukemiaCompletedNCT00154349Phase 2
- WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)Status unknownNCT00153582Phase 2
- Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous LeukemiaTerminatedNCT00152594Phase 3
- Stem Cell Transplantation for Patients With Hematologic MalignanciesCompletedNCT00152139Phase 3
- Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL)TerminatedNCT00151736Phase 2
- All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00151255Phase 3
- Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00151242Phase 2/3
- Standard vs. Reduced-Intensity Conditioning in Patients With Acute Myeloid Leukemia in First RemissionTerminatedNCT00150878Phase 3
- Treating Patients With Childhood Acute Myeloid Leukemia With Interleukin-2Status unknownNCT00149162Phase 3
- Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy.Status unknownNCT00149136Phase 2
- Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)CompletedNCT00147901Phase 2
- Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic ResultCompletedNCT00146120Phase 3
- Haploidentical Stem Cell Transplant for Treatment Refractory Hematological MalignanciesCompletedNCT00145613Phase 2
- A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL)CompletedNCT00145002Phase 3
- Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell TransplantationCompletedNCT00144703Phase 2
- Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell TransplantationCompletedNCT00144677Phase 2
- Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)CompletedNCT00143975Phase 2
- Stem Cell Transplantation as Immunotherapy for Hematologic MalignanciesCompletedNCT00143559Phase 2
- Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00143065Phase 2
- A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)CompletedNCT00136461Phase 2
- High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)CompletedNCT00136448Phase 2
- Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous LeukemiaCompletedNCT00136422Phase 1
- Study of Unrelated Cord Blood Transplantation Using Tacrolimus and SirolimusCompletedNCT00133367Phase 2
- Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00131989Phase 1
- Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.Status unknownNCT00131313Phase 4
- Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)Status unknownNCT00131053Phase 2
- High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)Status unknownNCT00131027Phase 3
- Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous LeukemiaCompletedNCT00130702Phase 2
- Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)CompletedNCT00130195Phase 2
- Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)TerminatedNCT00129948Phase 2
- A Study to Evaluate PT-523 in Patients With Refractory LeukemiaWithdrawnNCT00129558Phase 1/2
- Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT00129168Phase 1/2
- Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid LeukemiaTerminatedNCT00126893Phase 1
- BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's LymphomaCompletedNCT00126646Phase 1
- Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic CancerCompletedNCT00126477
- Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)Status unknownNCT00126321Phase 2
- Clofarabine in Adult Patients With Advanced Solid TumorsCompletedNCT00125840Phase 1
- Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT00124644Phase 1
- Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT00121303Phase 3
- Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00119340Phase 1/2
- Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous DiseaseCompletedNCT00118326Phase 1/2
- Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic LeukemiaTerminatedNCT00118196Phase 2
- Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous LeukemiaCompletedNCT00116467Phase 2
- Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)CompletedNCT00114764Phase 2
- ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic LeukemiaCompletedNCT00114348Phase 4
- Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative DisordersCompletedNCT00114257Phase 1
- Eculizumab in Treating Patients With Paroxysmal Nocturnal HemoglobinuriaCompletedNCT00112983Phase 3
- Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00112853Phase 1
- BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib MesylateStatus unknownNCT00112775Phase 2
- Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid TumorsTerminatedNCT00112619Phase 1
- Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00112567Phase 1/2
- Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00112554Phase 3
- Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and AdolescentsStatus unknownNCT00111345Phase 2/3
- Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous LeukemiaCompletedNCT00110058Phase 2
- Campath-1H + FK506 and Methylprednisolone for GVHDCompletedNCT00109993Phase 2
- Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)TerminatedNCT00109538Phase 3
- Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic LeukemiaStatus unknownNCT00109356Phase 1/2
- Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine TherapyTerminatedNCT00108108Phase 1
- Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00107523Phase 1
- Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell TransplantCompletedNCT00107354Phase 1
- Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)CompletedNCT00106600Phase 1/2
- Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/LeukemiaTerminatedNCT00105313Phase 1
- Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00104975Phase 1
- Fenretinide in Treating Patients With Refractory or Relapsed Hematologic CancerCompletedNCT00104923Phase 1
- Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML)TerminatedNCT00104468Phase 1/2
- BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic LeukemiaCompletedNCT00103701Phase 1
- Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)CompletedNCT00103558Phase 1/2
- 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic CancerTerminatedNCT00103272Phase 1
- Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic LeukemiaCompletedNCT00102661Phase 2
- Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaCompletedNCT00101595Phase 2
- Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00101296Phase 1
- Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaTerminatedNCT00101231Phase 1
- Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaTerminatedNCT00101205Phase 1
- MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid LeukemiaCompletedNCT00101179Phase 1
- Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00101153Phase 1
- Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in RemissionWithdrawnNCT00101140Phase 2
- Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00101088Phase 1
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib MesylateCompletedNCT00100997Phase 1
- Vaccine Therapy in Treating Patients With Acute Myeloid LeukemiaTerminatedNCT00100971Phase 1
- Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT00100711Phase 2
- Use of Topotecan in Patients With Refractory Acute LeukemiaCompletedNCT00100477Phase 2
- A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)TerminatedNCT00100152Phase 1
- MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or LymphomasCompletedNCT00098891Phase 1
- SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic SyndromesCompletedNCT00098826Phase 1
- 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic LeukemiaTerminatedNCT00098488Phase 1
- Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory LeukemiasCompletedNCT00098436Phase 1